Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Description of the sample

From: Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)

 

CO (n = 141)

SCD (n = 126)

MCI (n = 65)

AD (n = 40)

Relatives of AD patients (n = 22)

F value/χ2 value

Age (years), mean (SD)

68.6 (5.1)

71.4 (5.7)***

72.8 (5.2)***

72.8 (7.1)**

64.8 (4.5)**

15.4, p > 0.001

Sex (female), n (%)

83 (58.9)

65 (51.6)

25 (38.5)**

23 (57.5)

12 (54.5)

7.9, n.s.

Education (years), mean (SD)

15.0 (2,7)

14.7 (3.1)

14.1 (3.1)

13.2 (3.2)**

13.7 (2.6)*

3.78, p = 0.005

MMSE, mean (SD)

29.4 (0.9)

29.1 (1.0)

28.0 (1.6)***

23.6 (3.3)***

29.0 (1.2)

135, p < 0.001

CDR, mean (SD)

0.0 (0.0)

0.2 (0.2)***

0.5 (0.1)***

0.8 (0.2)***

0.1 (0.2)

216, p < 0.001

CDR-SOB, mean (SD)

0.0 (0.1)

0.4 (0.4)***

1.6 (1.2)***

4.7 (1.3)***

0.4 (1.0)

343, p < 0.001

ADAScog 13, mean (SD)

5.6 (3.3)

7.0 (3.9)**

15.3 (6.3)***

29.1 (8.1)***

8.0 (5.2)

220, p < 0.001

FAQ, mean (SD)

0.1 (0.4)

0.8 (1.2)***

3.5 (4.4)***

11.8 (6.2)***

0.4 (1.0)

154, p < 0.001

GDS, mean (SD)

0.7 (1.4)

1.9 (1.7)***

1.8 (1.6)***

2.1 (1.5)***

1.1 (1.3)

12.5, p < 0.001

APOE genotype

(n = 131)

(n = 114)

(n = 60)

(n = 36)

(n = 19)

 

 APOE4 genotype of all APOE, n (%)

23 (17.6)

37 (32.5)**

22 (36.7)**

25 (69.4)***

8 (42.1)*

37.3, p < 0.001

CSF biomarkers

(n = 50)

(n = 45)

(n = 35)

(n = 18)

(n = 6)

 

 Aβ42 (pg/ml), mean (SD)

890 (323)

748 (329)*

630*** (303)

353 (100)***

684 (415)

11.1, p < 0.001)

 Aβ42 < 496 pg/ml, n (%)

5 (10.0)

9 (20.0)

16 (45.7)***

18 (100)***

2 (33.3)

54.9, p < 0.001

 Aβ42/Aβ40, mean (SD)

0.099 (0.022)

0.093 (0.026)

0.077 (0.031)**

0.046 (0.015)***

0.077 (0.036)

16.0, p < 0.001

 Aβ42/Aβ40 < 0.09, n (%)

14 (28.0)

17 (37.8)

21 (60.0)**

17 (94.4)***

4 (66.7)

28.3, p < 0.001

 tTau (pg/ml), mean (SD)

359 (159)

366 (157)

502** (224)

742 (309)***

370 (108)

15.6, p < 0.001

 tTau > 470 pg/ml, n (%)

8 (16.0)

11 (24.4)

16 (45.7)**

15 (83.3)***

1 (16.7)

31.9, p < 0.001

 pTau 181 (pg/ml), mean (SD)

51 (20)

51 (24)

67 (33)*

91 (43)***

53 (16)

9.3, p < 0.001

 pTau 181 > 57 pg/ml, n (%)

15 (30.0)

14 (31.1)

20 (57.1)*

15 (83.3)***

3 (50.0)

20.9, p < 0.001

 Aβ42/Tau ratio, Hulstaert formula, mean (SD)

1.36 (0.38)

1.15 (0.47)*

0.84 (0.49)***

0.34 (0.14)***

1.03 (0.63)

22.0, p < 0.001

 Abnormal Aβ42/Tau ratio, Hulstaert formula, n (%)

7 (14.0)

16 (35.6)**

23 (65.7)***

18 (100)***

2 (33.3)

46.7, p < 0.001

  1. Post-hoc unadjusted p value in comparison to the control group: *p < 0.05, **p < 0.01, ***p < 0.001
  2. Aβ42 beta-amyloid 42, AD Alzheimer’s disease, ADAScog 13 Alzheimer’s Disease Assessment Scale—cognitive part, APOE apolipoprotein E, CDR Clinical Dementia Rating, CDR-SOB Clinical Dementia Rating—sum of boxes, CO control group, CSF cerebrospinal fluid, FAQ Functional Activities Questionnaire, GDS Geriatric Depression Scale, MCI mild cognitive impairment, MMSE Mini-Mental -State Examination, n.s. not significant, SCD subjective cognitive decline, SD standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193